for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Otsuka Holdings Co Ltd

4578.T

Latest Trade

4,653.00JPY

Change

-102.00(-2.15%)

Volume

1,400,700

Today's Range

4,650.00

 - 

4,721.00

52 Week Range

3,434.00

 - 

5,623.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Avanir Pharmaceuticals Announces Resolution of Government Investigation

Sept 26 (Reuters) - AVANIR PHARMACEUTICALS::AVANIR PHARMACEUTICALS - REACHED RESOLUTION OF CIVIL, CRIMINAL, AND ADMINISTRATIVE CLAIMS WITH FEDERAL GOVERNMENT & PARTICIPATING STATE AUTHORITIES.AVANIR PHARMACEUTICALS - TO PAY ABOUT $116 MILLION TO FEDERAL AND STATE GOVERNMENTS.AVANIR PHARMACEUTICALS - INDIVIDUALS LISTED IN RESOLUTION AGREEMENTS ARE NO LONGER AVANIR EMPLOYEES.AVANIR PHARMA - ENTERED INTO A FALSE CLAIMS ACT (FCA) AGREEMENT WITH VARIOUS GOVERNMENT AGENCIES AS PART OF RESOLUTION.AVANIR PHARMA - ENTERED INTO DEFERRED PROSECUTION AGREEMENT (DPA) WITH U.S. DOJ FOR PERIOD OF THREE YEARS.AVANIR PHARMA - ENTERED INTO CORPORATE INTEGRITY AGREEMENT WITH HHS-OIG FOR A PERIOD OF FIVE YEARS AS PART OF RESOLUTION.

Astex & Otsuka Announce Results Of Phase 3 Ascertain Study Of Novel Oral Cedazuridine/Decitabine Fixed-Dose Combination

June 6 (Reuters) - Astex Pharmaceuticals Inc::ASTEX AND OTSUKA ANNOUNCE RESULTS OF THE PHASE 3 ASCERTAIN STUDY OF THE NOVEL ORAL CEDAZURIDINE/DECITABINE FIXED-DOSE COMBINATION (ASTX727) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML).ASTEX - PLANS TO FILE A NEW DRUG APPLICATION (NDA) WITH US FDA BY END OF 2019.ASTEX PHARMACEUTICALS INC SAYS CEDAZURIDINE AND DECITABINE MET PRIMARY ENDPOINT IN STUDY.ASTEX PHARMA - STUDY CONFIRMED THAT SAFETY PROFILE OF CEDAZURIDINE & DECITABINE FIXED-DOSE COMBINATION WAS SIMILAR TO THAT OBSERVED IN PHASE 1/2 STUDY.

FDA Approves Taiho Oncology's Lonsurf For Adult Patients With Previously Treated Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma

Feb 25 (Reuters) - Otsuka Holdings Co Ltd <4578.T>::FDA APPROVES TAIHO ONCOLOGY'S LONSURF® (TRIFLURIDINE/TIPIRACIL) FOR ADULT PATIENTS WITH PREVIOUSLY TREATED ADVANCED GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA.TAIHO ONCOLOGY INC SAYS FDA APPROVAL OF CO'S LONSURF EXPANDS CURRENT INDICATION FOR LONSURF IN U.S..

Health Canada Approves Otsuka & Lundbeck's REXULTI As Adjunctive Treatment Of Major Depressive Disorder

Feb 22 (Reuters) - Otsuka::HEALTH CANADA APPROVES OTSUKA AND LUNDBECK'S REXULTI (BREXPIPRAZOLE) AS ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER.

Otsuka Holdings Co, Proteus Digital Health Report Expanded Collaboration Agreement

Oct 11 (Reuters) - Otsuka Holdings Co Ltd <4578.T>::OTSUKA AND PROTEUS DIGITAL HEALTH ANNOUNCE EXPANDED COLLABORATION AGREEMENT TO ADVANCE DIGITAL MEDICINES FOR MENTAL HEALTH.OTSUKA PHARMACEUTICAL SAYS AS PART OF EXPANDED COLLABORATION, CO MADE $88 MILLION IN RELATED EQUITY AND OTHER PAYMENTS TO PROTEUS.OTSUKA PHARMACEUTICAL - EXPANDED AGREEMENT COVERS DEVELOPMENT & COMMERCIALIZATION OF DIGITAL MEDICINES OVER NEXT 5 YEARS.

Otsuka Holdings to transfer stake management business to unit Otsuka Medical Devices

Sept 12 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says it will transfer ReCor Medical, Inc related stake management business to unit Otsuka Medical Devices Co Ltd, effective Nov. 1 .

DKSH: Otsuka Extends Partnership With DKSH In Hong Kong

Sept 6 (Reuters) - DKSH Holding AG <DKSH.S>::OTSUKA EXTENDS PARTNERSHIP WITH DKSH IN HONG KONG.

Otsuka Holdings unit completes acquisition of U.S.-based firm Visterra

Sept 3 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says its unit Otsuka Pharmaceutical Co., Ltd completed acquisition of U.S.-based firm Visterra Inc on Aug. 31 .

R&I affirms Otsuka Holdings' rating at "AA-" and says stable outlook-R&I

Aug 1 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-"-R&I.Rating outlook stable-R&I .

Astex Pharmaceuticals And Otsuka Announce Results Of The Phase 3 Astral-1 Study Of Guadecitabine In Treatment-Naïve AML Patients Ineligible To Receive Intense Induction Chemotherapy

July 30 (Reuters) - ASTEX PHARMACEUTICALS ::ASTEX PHARMACEUTICALS AND OTSUKA ANNOUNCE RESULTS OF THE PHASE 3 ASTRAL-1 STUDY OF GUADECITABINE (SGI-110) IN TREATMENT-NAÏVE AML PATIENTS INELIGIBLE TO RECEIVE INTENSE INDUCTION CHEMOTHERAPY.ASTEX PHARMACEUTICALS - STUDY DID NOT MEET ITS CO-PRIMARY ENDPOINTS.ASTEX PHARMACEUTICALS SAYS CONTINUES TO FOCUS ON COMPLETING PHASE 3 ASTRAL-2 AND ASTRAL-3 STUDIES.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up